Navigation Links
Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Date:3/6/2008

PALO ALTO, Calif., March 6 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) invites investors, media and the public to a live webcast of the company's 2008 investor meeting. The corporate presentation will begin at 10:00 a.m. Eastern Time/7:00 a.m. Pacific Time on Thursday, March 13, 2008. The meeting is expected to last approximately two hours.

Members of Jazz Pharmaceuticals' senior management team will provide a comprehensive overview of commercial and product development activities and a financial update, including:

-- a review of LUVOX(R) CR product launch activities;

-- an in-depth discussion of product candidates in development; and

-- 2008 financial guidance.

The live webcast may be accessed on Jazz Pharmaceuticals' website at http://www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the meeting to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archived version of the webcast will be available through March 27, 2008.

About Jazz Pharmaceuticals, Inc. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Benchworks ... 22 in Philadelphia. The event was offered by the Chamber of Commerce for ... featured breakout groups and interaction with speakers who are leaders in their industries. ...
(Date:3/28/2017)... 28, 2017 Volition America, Inc., a wholly-owned U.S. ... engagement of Deborah Vollmer Dahlke , DrPH, CEO and ... Vollmer Dahlke,s role will be to assist the ... State of Texas and elsewhere in ... has significant experience over the past six years, helping ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... initial release of LabKey’s newest software solution, LabKey Biologics . Built in ... pharma and biotech organizations, LabKey Biologics provides drug research teams tools for biological ...
(Date:3/28/2017)... ... March 28, 2017 , ... T3D Therapeutics, ... new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen ... we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease and ...
Breaking Biology Technology:
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
Breaking Biology News(10 mins):